These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 38037114)

  • 41. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 42. Deep learning-based prediction of the T cell receptor-antigen binding specificity.
    Lu T; Zhang Z; Zhu J; Wang Y; Jiang P; Xiao X; Bernatchez C; Heymach JV; Gibbons DL; Wang J; Xu L; Reuben A; Wang T
    Nat Mach Intell; 2021 Oct; 3(10):864-875. PubMed ID: 36003885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
    Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
    J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
    Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
    Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
    Baulu E; Gardet C; Chuvin N; Depil S
    Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell receptor-engineered T cells for cancer treatment: current status and future directions.
    Ping Y; Liu C; Zhang Y
    Protein Cell; 2018 Mar; 9(3):254-266. PubMed ID: 28108950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 52. [T cell receptor-based immunotherapy: a review].
    Chen Y; Gao GF; Tan S
    Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4004-4028. PubMed ID: 37877387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells.
    Paria BC; Levin N; Lowery FJ; Pasetto A; Deniger DC; Parkhurst MR; Yossef R; Kim SP; Florentin M; Ngo LT; Ray S; Krishna S; Robbins PF; Rosenberg SA
    J Immunother; 2021 Jan; 44(1):1-8. PubMed ID: 33086340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
    Hiltensperger M; Krackhardt AM
    Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
    Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
    Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.
    Poran A; Scherer J; Bushway ME; Besada R; Balogh KN; Wanamaker A; Williams RG; Prabhakara J; Ott PA; Hu-Lieskovan S; Khondker ZS; Gaynor RB; Rooney MS; Srinivasan L
    Cell Rep Med; 2020 Nov; 1(8):100141. PubMed ID: 33294862
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalized immunotherapy in cancer precision medicine.
    Kiyotani K; Toyoshima Y; Nakamura Y
    Cancer Biol Med; 2021 Aug; 18(4):955-65. PubMed ID: 34369137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting cancers through TCR-peptide/MHC interactions.
    He Q; Jiang X; Zhou X; Weng J
    J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.